首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Profile of multi drug resistant (MDR) and rifampicin resistant TB patients treated under category IV of RNTCP
【24h】

Profile of multi drug resistant (MDR) and rifampicin resistant TB patients treated under category IV of RNTCP

机译:RNTCP IV类治疗的耐多药(MDR)和耐利福平(TB)的结核病患者的概况

获取原文
           

摘要

Background: The emergence of resistance to drugs used to treat tuberculosis (TB) and particularly multidrug resistance TB (MDR-TB) has become a significant health problem and obstacle to effective TB control in India. Present study was conducted to study clinical and sociodemograohic profile of MDR and rifampicin resistant TB patients registered for treatment under RNTCP in Yavatmal district of Maharashtra state. Methods: All drug resistant (MDR and rifampicin resistant) TB patients residents of Yavatmal district, treated at DOTS plus site with Standardized Treatment Regimen (STR) from 1st quarter 2009 to 3 rd quarter 2013 were included. Data was obtained from electronic treatment register maintained at DOTS Plus site. Results: There were total 60 confirmed MDR and rifampicin resistant TB patients from Yavatmal district. Male patients (65.00%) were comparatively more than females (35.00%). Almost half (46.67%) of the patients belonged to the productive age group i.e. 30-45 years followed by another one third (35.00%) in the age group of 15-30 years. 93.33% patients were previously treated under RNTCP (under CAT II), out of them 48.51% were failure, 37.50% relapse and 14.29% defaulter. Conclusions: Among MDR and rifampicin resistant TB patients, maximum patients were males, belonged to the social and productive age group, HIV negative and previously treated due to treatment failure.
机译:背景:对用于治疗结核病(TB)的药物,特别是对多药耐药性结核病(MDR-TB)的耐药性的出现,已经成为印度的重要健康问题,成为有效控制结核病的障碍。目前的研究是在马哈拉施特拉邦Yavatmal区研究登记为接受RNTCP治疗的耐多药结核病和耐利福平的结核病患者的临床和社会人口动态。方法:纳入2009年第1季度至2013年第3季度在DOTS plus站点接受标准化治疗方案(STR)治疗的Yavatmal地区的所有耐药(耐MDR和耐利福平)结核病患者。数据是从DOTS Plus网站上维护的电子治疗记录中获得的。结果:Yavatmal地区共有60例确诊的MDR和耐利福平的结核病患者。男性患者(65.00%)比女性患者(35.00%)相对多。将近一半(46.67%)的患者属于生产年龄组,即30-45岁,其次是15-30岁年龄组的三分之一(35.00%)。 93.33%的患者先前接受过RNTCP(根据CAT II)治疗,其中48.51%为失败,37.50%复发和14.29%违约。结论:耐多药和耐利福平的结核病患者中,男性最多,属于社会和生产年龄组,HIV阴性且因治疗失败而接受过治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号